Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study

Merck (MRK) announced that the phase III KEYLYNK-006 study, evaluating the combination of its blockbuster drugs Keytruda and Lynparza in certain non-small cell lung cancer (NSCLC) patients, failed to meet its primary endpoints.The KEYLYNK-006 study evaluated Keytruda, combined with Lynparza as maintenance therapy, for the first-line treatment for patients with metastatic non-squamous NSCLC with no EGFR, ALK or ROS1 genomic tumor aberrations. Patients in the control group received pemetrexed chemotherapy ins ...